Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

310

Enrollment

INDUSTRY

Sponsor class

Conditions

Perennial Allergic Rhinitis

Interventions

DRUG: Ciclesonide HFA Nasal Aerosol 320 mcg
DRUG: Ciclesonide HFA Nasal Aerosol 160 mcg
DRUG: HFA Nasal Aerosol placebo
DRUG: Ciclesonide Aqueous Nasal Spray 200 mcg
DRUG: AQ Nasal Spray Placebo
DRUG: Placebo plus Dexamethasone HFA
DRUG: Placebo AQ plus Dexamethasone 6 mg

Sponsor

Sumitomo Pharma America, Inc.